Good morning. We’re sending the newsletter a bit early today since we’ve got some breaking news for you — plus a new FDA commissioner nominee.

Merck and Moderna’s mRNA cancer vaccine succeeds in late-stage trial

Scientists have long hoped that personalized mRNA cancer vaccines could be the next big breakthrough in oncology treatment. Today, Merck and Moderna said they had shown in a randomized late-stage trial for the first time that such a drug can work.